David Risinger

“So I have three questions, but rather than rattling them all off right now, maybe if it's okay, I'll go one by one. So first, on Moseley, you commented just now on six-minute walk distance.”

“So, Chris, regarding milvexian and atrial fibrillation, you had stated in your prepared remarks, quote, an independent data monitoring committee continues to endorse the study, and with the passage of time as the study progresses, we are increasingly encouraged about milvexian, end quote.”

“Yes, thanks very much, and congrats, Helen, to you and your team on all the great fundamental momentum in the business and new contract signings. So I have a few questions.”

“So my question is on J&J 4804, the co-antibody. Could you talk about your vision for its role in IBD treatment paradigms and the readouts that we should be focused on?”

“So, congrats on the financial updates, Helen. I had two questions, please. First, you had set initially the 2028 targets back in 2024. So can you comment on why you're not rolling annual targets out to 2030 today?”